Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
537
Recruiting Now
537
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07655115 Phase 3
Recruiting
Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability ...
Condition
Autism Spectrum Disorders
Enrollment
103 pts
Location
France, Spain
Sponsor
Hospital General Universitario
NCT07086976 Phase 3
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzab...
Condition
Autoimmune Haemolytic Anaemia
Enrollment
90 pts
Location
United States, Argentina, Austria
Sponsor
Sanofi
NCT07645248 Phase 3
Recruiting
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...
Condition
Asthma
Enrollment
110 pts
Location
United States, Argentina, Canada
Sponsor
GlaxoSmithKline
NCT07262476 Phase 3
Recruiting
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Condition
Thyroid Eye Disease (TED)
Enrollment
258 pts
Location
China
Sponsor
Minghui Pharmaceutical (Hangzh
NCT07296458 Phase 3
Recruiting
FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PB...
Condition
Primary Biliary Cholangitis (PBC)
Enrollment
132 pts
Location
China
Sponsor
Xijing Hospital of Digestive D
NCT05916963 Phase 3
Recruiting
Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureterosc...
Condition
Kidney Stone
Enrollment
374 pts
Location
France
Sponsor
University Hospital, Tours
NCT06969287 Phase 3
Recruiting
Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery
Condition
Delirium
Enrollment
46 pts
Location
United States
Sponsor
Washington University School o
NCT07478991 Phase 3
Recruiting
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pa...
Condition
Acute Myeloid Leukemia, Adult
Enrollment
376 pts
Location
Spain
Sponsor
PETHEMA Foundation
NCT07877818 Phase 3
Recruiting
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adj...
Condition
Gastric
Enrollment
140 pts
Location
China
Sponsor
AstraZeneca
NCT07140913 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatmen...
Condition
Mania
Enrollment
424 pts
Location
United States, Argentina, Bulgaria
Sponsor
Bristol-Myers Squibb
NCT07629440 Phase 3
Recruiting
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Condition
Pneumococcal Disease
Enrollment
3,230 pts
Location
United States, Japan, Puerto Rico
Sponsor
Pfizer
NCT03619850 Phase 3
Recruiting
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmaco...
Condition
Chronic Kidney Disease; Iron Deficiency Anemia
Enrollment
129 pts
Location
United States, Hungary, Lithuania
Sponsor
AMAG Pharmaceuticals, Inc.
NCT07509840 Phase 3
Recruiting
Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Wo...
Condition
Autoimmune Prematur Ovarian Insuffience
Enrollment
40 pts
Location
Sweden
Sponsor
Angelica Lindén Hirschberg
NCT07309289 Phase 3
Recruiting
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-lin...
Condition
Metastatic Colorectal Cancer (CRC)
Enrollment
144 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
NCT06334497 Phase 3
Recruiting
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
Condition
Cytomegalovirus Infection
Enrollment
80 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT07518147 Phase 3
Recruiting
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen i...
Condition
Gastric Cancer
Enrollment
438 pts
Location
China
Sponsor
Biokin (Shanghai) Biopharmaceu
NCT05028140 Phase 3
Recruiting
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes...
Condition
Type II Diabetes
Enrollment
480 pts
Location
Brazil
Sponsor
EMS
NCT06568315 Phase 3
Recruiting
Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal...
Condition
Anemia, Iron Deficiency
Enrollment
3,200 pts
Location
Burkina Faso, Pakistan
Sponsor
Johns Hopkins Bloomberg School
NCT06830889 Phase 3
Recruiting
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Brea...
Condition
HER2-positive Breast Cancer
Enrollment
1,450 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C
NCT07105098 Phase 3
Recruiting
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph...
Condition
Schizophrenia
Enrollment
284 pts
Location
United States, Bulgaria, Hungary
Sponsor
Neurocrine Biosciences
NCT06314906 Phase 3
Recruiting
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and V...
Condition
Electroacupuncture
Enrollment
370 pts
Location
China
Sponsor
Feixue Song
NCT06312176 Phase 3
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combinatio...
Condition
Breast Neoplasms
Enrollment
1,200 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT06729840 Phase 3
Recruiting
Intralesional Treatment of Keloids
Condition
Scar, Hypertrophic
Enrollment
45 pts
Location
Egypt
Sponsor
Sohag University
NCT06793917 Phase 3
Recruiting
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Mult...
Condition
Gastric Cancer
Enrollment
269 pts
Location
China
Sponsor
Fujian Cancer Hospital
NCT06570889 Phase 3
Recruiting
VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma
Condition
Asthma
Enrollment
2,000 pts
Location
Denmark
Sponsor
Professor Klaus Bønnelykke
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology